Advanz aims to grow after Concordia switch

Concordia International is looking to invest in licensing and co-development deals, as well as in product and company acquisitions, as it seeks to revive its fortunes under the new Advanz Pharma brand following the completion of a recapitalisation transaction that took place in early September.

Concordia International is looking to invest in licensing and co-development deals, as well as in product and company acquisitions, as it seeks to revive its fortunes under the new Advanz Pharma brand following the completion of a recapitalisation transaction that took place in early September.

Chief executive officer Graeme Duncan acknowledged that Concordia had “been through a tough time for the past two and a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Wockhardt Pivots To Biosimilar Insulins Focus As It Confirms US Generics Exit

 
• By 

Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By 

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.